Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Singapore's Parkway Pantai Sees Luxury Hospital Opportunities In China

This article was originally published in PharmAsia News

Executive Summary

SINGAPORE - Parkway Pantai Ltd. CEO Tan See Leng has set his sights on ambitious expansion beyond the company's primary markets in Singapore and Malaysia, including a luxury hospital in China that he equates to the hotel chain Shangri-La Hotels

You may also be interested in...

United Family Healthcare’s David Rutstein On Developing China’s Private Health Sector: An Interview With PharmAsia News (Part 2 of 2)

The vice president for Medical Affairs discusses the recent Chindex Internationa merger, the challenges and opportunities that the company faces to meet the need for more private health care, as the central government ramps up spending and attitudes toward health insurance and medical incentives change.

China's Changing Reimbursement Landscape Reshapes Pharma Market

SHANGHAI - China's prescription drugs market has seen a slowdown in growth in large cities due to implementation of government pilot reimbursement projects that could be adopted nationwide, according to a Sept. 27 Citi report

New Guidelines Shed Light On Private Investment In China Hospitals

SHANGHAI - China's capital Beijing and Zhejiang Province recently issued long-awaited guidelines to encourage private investment in medical institutions, which is viewed by analysts as a signal that China will implement the policy nationwide and open the gates for private hospitals

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts